These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 16799653)
21. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370 [TBL] [Abstract][Full Text] [Related]
22. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors). Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105 [TBL] [Abstract][Full Text] [Related]
23. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases. Fan XM; Zhang J; Niu SH; Li KX; Song CZ Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999 [TBL] [Abstract][Full Text] [Related]
24. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy. Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676 [TBL] [Abstract][Full Text] [Related]
25. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience. Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887 [TBL] [Abstract][Full Text] [Related]
27. Cytoreductive surgery in advanced stage malignant ovarian germ cell tumors. Karalok A; Comert GK; Kilic C; Turkmen O; Kilic F; Basaran D; Boyraz G; Tekin ÖM; Turan T J Gynecol Obstet Hum Reprod; 2019 Sep; 48(7):461-466. PubMed ID: 31228608 [TBL] [Abstract][Full Text] [Related]
28. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244 [TBL] [Abstract][Full Text] [Related]
29. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Ryu KS; Kim JH; Ko HS; Kim JW; Ahn WS; Park YG; Kim SJ; Lee JM Gynecol Oncol; 2004 Aug; 94(2):325-32. PubMed ID: 15297169 [TBL] [Abstract][Full Text] [Related]
30. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma. Todo Y; Sakuragi N; Oikawa M; Negishi H; Yamamoto R; Yoshiaki K; Tsumura N; Kawaguchi I; Fujimoto S Int J Clin Oncol; 2003 Apr; 8(2):90-6. PubMed ID: 12720101 [TBL] [Abstract][Full Text] [Related]
31. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Schilder JM; Thompson AM; DePriest PD; Ueland FR; Cibull ML; Kryscio RJ; Modesitt SC; Lu KH; Geisler JP; Higgins RV; Magtibay PM; Cohn DE; Powell MA; Chu C; Stehman FB; van Nagell J Gynecol Oncol; 2002 Oct; 87(1):1-7. PubMed ID: 12468335 [TBL] [Abstract][Full Text] [Related]
32. A case report of recurrent epithelial ovarian cancer metastatic to the sternum, diaphragm, costae, and bowel managed by aggressive secondary cytoreductive surgery without postoperative chemotherapy. Sher-Ahmed A; Buscema J; Sardi A Gynecol Oncol; 2002 Jul; 86(1):91-4. PubMed ID: 12079306 [TBL] [Abstract][Full Text] [Related]
33. Rectosigmoidectomy and Douglas Peritonectomy in the Management of Serosal Implants in Advanced-Stage Ovarian Cancer Surgery: Survival and Surgical Outcomes. Erkilinç S; Karataşli V; Demir B; Çakir İ; Can B; Karadeniz T; Gökçü M; Sanci M Int J Gynecol Cancer; 2018 Nov; 28(9):1699-1705. PubMed ID: 30371561 [TBL] [Abstract][Full Text] [Related]
34. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Gerestein CG; Nieuwenhuyzen-de Boer GM; Eijkemans MJ; Kooi GS; Burger CW Eur J Cancer; 2010 Jan; 46(1):102-9. PubMed ID: 19900801 [TBL] [Abstract][Full Text] [Related]
35. Surgical treatment of advanced ovarian cancer. David L; Dinu I; Vatachki G; Lungu V; Toader C; Popescu I Khirurgiia (Sofiia); 2013; (2):4-11. PubMed ID: 24151743 [TBL] [Abstract][Full Text] [Related]
36. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer. Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899 [TBL] [Abstract][Full Text] [Related]
37. [Surgery in early-stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. Bolze PA; Collinet P; Golfier F; Bourgin C Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):168-179. PubMed ID: 30686727 [TBL] [Abstract][Full Text] [Related]
38. Peritoneal Involvement Is More Common Than Nodal Involvement in Patients With High-Grade Appendix Tumors Who Are Undergoing Prophylactic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Mehta A; Mittal R; Chandrakumaran K; Carr N; Dayal S; Mohamed F; Moran B; Cecil T Dis Colon Rectum; 2017 Nov; 60(11):1155-1161. PubMed ID: 28991079 [TBL] [Abstract][Full Text] [Related]
39. [Application of laparoscopic exploration combined with abdominal exfoliative cytology in the diagnosis and treatment of locally advanced gastric cancer]. Ding PA; Liu Y; Guo HH; Yang PG; Tian Y; Fan LQ; Tan BB; Li Y; Zhao Q Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Feb; 23(2):170-176. PubMed ID: 32074798 [No Abstract] [Full Text] [Related]
40. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Chang SJ; Bristow RE; Ryu HS Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]